These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 23144741)

  • 1. Potentiation of thrombin generation in hemophilia A plasma by coagulation factor VIII and characterization of antibody-specific inhibition.
    Doshi BS; Gangadharan B; Doering CB; Meeks SL
    PLoS One; 2012; 7(10):e48172. PubMed ID: 23144741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
    Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
    Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
    Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
    Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
    J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
    Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
    Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
    Klintman J; Astermark J; Berntorp E
    Br J Haematol; 2010 Nov; 151(4):381-6. PubMed ID: 20977448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.
    Turecek PL; Váradi K; Keil B; Negrier C; Berntorp E; Astermark J; Bordet JC; Morfini M; Linari S; Schwarz HP
    Pathophysiol Haemost Thromb; 2003; 33(1):16-22. PubMed ID: 12853708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
    Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
    J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.
    Gangadharan B; Delignat S; Ollivier V; Gupta N; Mackman N; Kaveri SV; Lacroix-Desmazes S
    J Thromb Haemost; 2014 Dec; 12(12):2065-9. PubMed ID: 25267332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diversity of the immune response to the A2 domain of human factor VIII.
    Markovitz RC; Healey JF; Parker ET; Meeks SL; Lollar P
    Blood; 2013 Apr; 121(14):2785-95. PubMed ID: 23349389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype.
    Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS
    Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.
    Zakas PM; Vanijcharoenkarn K; Markovitz RC; Meeks SL; Doering CB
    J Thromb Haemost; 2015 Jan; 13(1):72-81. PubMed ID: 25315236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
    Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
    J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
    Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
    Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors.
    Batsuli G; Deng W; Healey JF; Parker ET; Baldwin WH; Cox C; Nguyen B; Kahle J; Königs C; Li R; Lollar P; Meeks SL
    Blood; 2016 Oct; 128(16):2055-2067. PubMed ID: 27381905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.